 |
인쇄하기
취소
|
Sebivo demonstrated better antiviral activity compared to lamivudine in patients with hepatitis
Handok Pharm announced on March 9 new clinical data of Sebivo (telbivudine) for 24 weeks of treatment of chronic hepatitis B (CHB). Handok is a co-distributor of Sebivo in Korea.
Data from the second year of the phase III GLOBE study in patients with 1,367 patients from 20 countries suggest that viral clearance within the 24 weeks of therapy is associated with better outcomes at two years of...
Data from the second year of the phase III GLOBE study in patients with 1,367 patients from 20 countries suggest that viral clearance within the 24 weeks of therapy is associated with better outcomes at two years of...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.